VNDA FY 2020 Earnings Report — Vanda Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

Vanda Pharmaceuticals Inc.VNDA

FY 2020 Earnings

Reported February 11, 2021

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2020	Prior Q	FY 2019	QoQ Change	YoY Change
Revenue	$248M	—	$227M	—	9.2%
Op. Income	$27M	—	$23M	—	19.4%
Gross Margin	90.6%	—	89.2%	—	1.4pp
Net Margin	9.4%	—	50.9%	—	-41.5pp
EPS (Diluted)	$0.42	—	$2.11	—	-80.1%
Free Cash Flow	$50M	—	$45M	—	11.2%

Revenue Flow

Item	Amount
REVENUE	$248M
Cost of Revenue	$23M
GROSS PROFIT	$225M
R&D Expenses	$56M
Selling & Marketing	$13M
General & Administrative	$128M
SG&A Expenses	$141M
Other Expenses	$1M
Operating Expenses	$198M
Cost & Expenses	$221M
OPERATING INCOME	$27M
Interest Income	$4M
Interest Expense	$0
Other Income/Expenses	$4M
INCOME BEFORE TAX	$32M
Income Tax Expense	$8M
Net Income from Continuing Ops	$23M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$23M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$23M
D&A	$3M
EBIT	$32M
EBITDA	$35M
EPS	$0
EPS Diluted	$0

Income Statement

Item	Amount
REVENUE	$248M
Cost of Revenue	$23M
GROSS PROFIT	$225M
R&D Expenses	$56M
Selling & Marketing	$13M
General & Administrative	$128M
SG&A Expenses	$141M
Other Expenses	$1M
Operating Expenses	$198M
Cost & Expenses	$221M
OPERATING INCOME	$27M
Interest Income	$4M
Interest Expense	$0
Other Income/Expenses	$4M
INCOME BEFORE TAX	$32M
Income Tax Expense	$8M
Net Income from Continuing Ops	$23M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$23M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$23M
D&A	$3M
EBIT	$32M
EBITDA	$35M
EPS	$0
EPS Diluted	$0

Cash Flow Statement

Item	Amount
Net Income	$23M
Depreciation & Amortization	$3M
Stock-Based Compensation	$13M
Deferred Income Tax	$6M
Other Non-Cash Items	$2M
Change in Working Capital	$4M
OPERATING CASH FLOW	$52M
Capital Expenditure	-$2M
Acquisitions (Net)	$0
Purchases of Investments	-$347M
Sales/Maturities of Investments	$307M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$41M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$6M
FREE CASH FLOW	$50M
Net Change in Cash	$16M

Balance Sheet

Item	Amount
Cash & Equivalents	$61M
Short-Term Investments	$307M
Net Receivables	$30M
Inventory	$1M
Other Current Assets	$0
TOTAL CURRENT ASSETS	$409M
PP&E (Net)	$15M
Goodwill	$0
Intangible Assets	$22M
Long-Term Investments	$0
Tax Assets	$82M
Other Non-Current Assets	$7M
TOTAL NON-CURRENT ASSETS	$124M
TOTAL ASSETS	$533M
Account Payables	$1M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$45M
TOTAL CURRENT LIABILITIES	$66M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$3M
TOTAL NON-CURRENT LIABILITIES	$14M
TOTAL LIABILITIES	$80M
Common Stock	$55.0K
Additional Paid-In Capital	$650M
Retained Earnings	-$197M
Treasury Stock	$0
Accum. Other Comp. Income	$239.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$453M
Minority Interest	$0
TOTAL EQUITY	$453M
TOTAL LIABILITIES & EQUITY	$533M
Total Debt	$14M
Net Debt	-$47M